Breast Cancer
Research activity includes early-stage HER2-positive breast cancer, hormone receptor-positive and HER2-negative breast cancer with low recurrence score, and node-positive breast cancer with 1-3 positive nodes. The funded trials focus on neoadjuvant therapy, endocrine therapy, and decisions about the role of chemotherapy in recurrence risk.
- HER2-positive disease
- Hormone receptor-positive breast cancer
- Node-positive breast cancer
Clinical interest also extends to treatment selection guided by tumour biology and risk of relapse.
Prostate Cancer
The portfolio covers localised very high-risk prostate cancer, localised prostate cancer at high risk of recurrence, and metastatic prostate cancer. Studies examine androgen deprivation therapy, radiation therapy, and systemic treatment strategies in both curative-intent and advanced settings.
- Very high-risk localised prostate cancer
- Metastatic prostate cancer
- Radiation-based treatment combinations
These trials address disease control, recurrence prevention, and survival outcomes across different stages of prostate malignancy.
Haematological Malignancies
Research funding includes newly diagnosed multiple myeloma and relapsed/refractory multiple myeloma. The studies focus on induction therapy, response depth, and treatment options for disease that has returned or no longer responds to prior therapy.
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Response assessment
Therapeutic interest centres on combination regimens used to improve disease control in plasma cell disorders.
Solid Tumours and Advanced Disease
Additional studies involve advanced head and neck cancer, high-risk resected melanoma, metastatic refractory pancreatic cancer, and low-grade serous carcinoma of the ovary or peritoneum. The clinical focus includes immunotherapy, radiation-based treatment, and management of recurrent or treatment-resistant disease.
- Advanced head and neck cancer
- High-risk resected melanoma
- Metastatic refractory pancreatic cancer
- Low-grade serous carcinoma
These areas reflect interest in both post-surgical risk reduction and treatment options for metastatic or resistant malignancies.
